Last reviewed · How we verify
conbercept, Fixed
Conbercept is a recombinant human VEGF decoy receptor that inhibits angiogenesis.
Conbercept is a recombinant human VEGF decoy receptor that inhibits angiogenesis. Used for Diabetic macular edema.
At a glance
| Generic name | conbercept, Fixed |
|---|---|
| Sponsor | Chengdu Kanghong Biotech Co., Ltd. |
| Drug class | VEGF decoy receptor |
| Target | VEGF |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Conbercept works by binding to vascular endothelial growth factor (VEGF) and preventing it from interacting with its receptors on the surface of endothelial cells, thereby inhibiting angiogenesis. This mechanism of action is thought to be responsible for its anti-tumor and anti-angiogenic effects.
Approved indications
- Diabetic macular edema
Common side effects
- conjunctival hemorrhage
- eye pain
- conjunctival hyperemia
Key clinical trials
- Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema (NA)
- A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |